The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2020

Genetic Counselors' Approaches to Direct-to-Consumer Genetic
Testing for Hereditary Breast Cancer
Sarah Burke

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medical Genetics Commons, and the Oncology Commons

Recommended Citation
Burke, Sarah, "Genetic Counselors' Approaches to Direct-to-Consumer Genetic Testing for Hereditary
Breast Cancer" (2020). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open Access). 1001.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1001

This Thesis (MS) is brought to you for free and open
access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

GENETIC COUNSELORS’ APPROACHES TO DIRECT-TOCONSUMER GENETIC TESTING FOR HEREDITARY BREAST CANCER

by
Sarah Burke, B.S.

APPROVED:
______________________________
Maureen Mork, M.S., C.G.C
Advisory Professor
______________________________
Meagan Kaulfus, M.S., C.G.C
______________________________
Krista Qualmann, M.S., C.G.C
______________________________
Ashley Woodson, M.S., C.G.C
______________________________
Min Jin Ha, Ph.D.
______________________________
Banu Arun, M.D

APPROVED:
______________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

GENETIC COUNSELORS’ APPROACHES TO DIRECT-TOCONSUMER GENETIC TESTING FOR HEREDITARY BREAST CANCER

A
THESIS
Presented to the Faculty of
The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
MASTER OF SCIENCE

by
Sarah Burke, Bachelor of Science
Houston, Texas

May 2020

ACKNOWLEDGEMENTS
This thesis reflects the collaboration and guidance from many talented individuals. In
particular, I would like to thank Meagan Kaulfus for her original idea that initiated this project.
Meagan has been the most wonderful source of encouragement, insight, and advice, all while
supporting my independent ownership of this research and mentoring me along the way. I am
so thankful, Meagan, for the time you have spent assisting me with this project and my overall
genetic counseling development. I would also like to thank my committee members: Maureen
Mork, Krista Qualmann, Ashley Woodson, Min Jin Ha, and Banu Arun for their time and
contributions that aided in the accomplishment of this research.
I am grateful to the University of Texas Genetic Counseling Program and our leaders,
Claire Singletary and Jennifer Czerwinski. The Class of 2020 had quite the ride, but it has
been your guidance that not only saw us through, but helped shape us into thoughtful,
empathetic, knowledgeable, and confident genetic counselors. I am also eternally thankful to
each of the supervisors in our program that taught us the skills we will carry with us long after
our training.
I must also acknowledge my family and friends, for it is through their unconditional
love and support that I have been able to turn my dreams into my reality. To my parents, Jim
and Jackie Burke, thank you from the deepest part of my heart for providing me with the
opportunities in life to achieve all that I wanted, even when it brought me to Texas. I am also
lucky to have two brothers that supported me. To my classmates (Wendi, Caroline, Autumn,
Brad, Aranza, Emily, Kaitlyn, Luke, Addison) - we did it! I am lucky to have experienced this
crazy ride called graduate school with each of you.

iii
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ABSTRACT
Given the increasing availability of health-related direct-to-consumer genetic testing
(DTC-GT) and third-party interpretation (TPI) services, it is likely that genetic counselors
(GCs) will continue to encounter consumers that require follow-up counseling for their results.
The National Comprehensive Cancer Network recommends clinical-grade genetic testing to
confirm commercial results; however, the type of testing that GCs select remains
uncharacterized. Therefore, we aimed to describe the specific recommendations that cancer
GCs make for confirmatory genetic testing in probands who have already obtained DTC-GT
results or TPI data that reported a BRCA1/2 pathogenic variant. We recruited 80 GCs
specializing in hereditary cancer and administered a survey that assessed their testing strategy
for probands from three hypothetical case scenarios with variable personal and family histories
of cancer. The majority of participants would recommend confirmatory clinical-grade genetic
testing for both probands’ DTC-GT results and TPI data (77/80, 96%). For probands with a
personal diagnosis of breast cancer and a DTC-GT result for an Ashkenazi Jewish BRCA1/2
founder mutation, participants were more likely to recommend targeted testing (single-site or
comprehensive BRCA1/2 analysis) (30/77, 39%, p < 0.01). In scenarios where probands had
DTC-GT results but lacked a personal and/or family history suggestive of hereditary cancer,
and in all scenarios where the probands had positive TPI data for a BRCA1/2 variant, most
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GCs would recommend a multi-gene panel. Our results show that GCs are unified in their
practice of recommending confirmatory genetic testing, although the selected clinical-grade
test varies depending on the proband’s cancer history and type of commercial testing they
obtained. As the market for DTC-GT expands and this patient population continues to grow,
genetic counselors must continue to be knowledgeable on this topic.
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INTRODUCTION
Direct-to-consumer genetic testing (DTC-GT) has fundamentally changed the way that
individuals can obtain personal genetic information, which may include predictions about their
health. The DTC-GT company 23andMe issues personalized health reports for various
multifactorial conditions and single-gene disorders. Many DTC-GT companies also provide
the option to download raw genotype data. It is estimated that as many as 60% of consumers
would be interested in utilizing online third-party interpretation (TPI) services to further
analyze their raw data to obtain additional health information not included in their original
DTC-GT report (Wang et al., 2018).
An important concern from healthcare providers related to DTC-GT is the
methodology of this testing. Whereas clinical diagnostic testing is ordered as part of a medical
evaluation and typically includes comprehensive full-gene sequencing with deletion and
duplication analyses, DTC-GT utilizes genotyping of common single nucleotide
polymorphisms (SNPs) to provide information to generally healthy individuals (Carere et al.,
2015). 23andMe offers testing for hereditary breast and ovarian cancer (HBOC) syndrome, but
only includes genotyping of the three Ashkenazi Jewish (AJ) founder mutations. This
limitation may create false reassurance for consumers with negative results as there are
thousands of disease-causing BRCA1/2 variants not assessed by this test (Horton et al., 2019).
Further, TPI services function by cross-referencing raw genotype data with public databases,
such as SNPedia wiki, to provide classifications on the reported variants. However, the
majority of classifications in some databases may be incorrect (Badalato et al., 2017;
Dorschner 2013; Moscarello, Murray, Reuter, & Demo, 2019; Wang et al., 2017). The
misclassification of such variants contributes to Tandy-Connor et al.’s (2018) finding that as
many as 40% of the reported variants from TPI data are false positives. For these reasons, the
1

National Comprehensive Cancer Network (NCCN) recommends confirmatory germline testing
through an appropriately certified clinical-grade laboratory when potentially pathogenic
variants are identified by commercial entities (NCCN, 2020). Other concerns related to these
services include an inadequate informed consent process, questionable clinical validity and
utility, and potential misuse of false positive results (Badalato, Kalokairinou, & Borry, 2017;
Horton et al., 2019).
Despite these considerations, the DTC-GT delivery model has become increasingly
accessible. More than 14 million people have utilized DTC-GT, and that figure is expected to
reach 100 million by 2021 (Khan & Mittelman, 2018). The majority of DTC-GT companies
recommend discussion of results with a healthcare provider (Singleton et al., 2012), and
approximately one-third of this large consumer base will share their report with a provider
(Bloss et al., 2013; Wang et al., 2018). In an effort to understand which practitioners most
frequently encounter DTC-GT results, Van der Wouden et al. (2012) reported that the majority
of consumers planned to share their health-related results with their primary care physician
(PCP). However, most PCPs reported a lack of knowledge regarding DTC-GT reports (Carroll
et al., 2016; Powell et al., 2012). In contrast, genetic counselors (GCs) undergo extensive
training to explain the potential implications of genetic test results, including medical
management, screening, preventative care, and how family members may be affected (Ramos
& Weissman, 2018); however, no study to date has surveyed GCs’ perceived comfort level
regarding counseling patients on DTC-GT reports. Nonetheless, given their training and
skillset, GCs may be the most capable provider to bridge the gap between patients and their
DTC-GT result and/or TPI data. Thus, the National Society of Genetic Counselors (NSGC)
advises consumers interested in learning additional information about their individualized
health-related risks to consult with a GC (NSGC, 2018).
2

Despite this recommendation from NSGC, it remains unknown how GCs are
incorporating DTC-GT results and TPI data into their clinical practice. The field of hereditary
breast cancer is well-suited to further study of this topic. Testing for HBOC syndrome is
widely available through DTC-GT companies, the majority of TPI data false-positives occur in
BRCA1/2 (Tandy-Connor et al., 2018), and there are implications for actionable medical
management once affected individuals are identified. The purpose of this study is to describe
what recommendations, if any, GCs make for clinical-grade genetic testing in patients who
have already obtained DTC-GT results or TPI data that reported a BRCA1/2 pathogenic variant
in order to help inform counseling approaches and consensus for this expanding group of
patients.
METHODS
Participants
This study was approved by the institutional review board at the University of Texas
Health Science Center at Houston (HSC-GEN-19-0445). Participants were recruited via an
email that contained a survey link distributed to all members of NSGC in the United States and
Canada. Eligible participants included practicing GCs reporting clinical cancer genetics as
their primary specialty, defined as greater than 50% of their time. Responses were collected
from August to November 2019.
Instrumentation
This study employed a cross-sectional design with an anonymous survey that was
created using Qualtrics software (v. July 2019. Qualtrics, Provo, UT). Survey questions were
created by the authors and a formal validated measure was not used given the unique aims of
this study. Participants were asked about demographic information, experience with DTC-GT
results and TPI data in clinic, and three hypothetical case scenarios. They were also given
3

Likert scales to assess perceived challenges associated with counseling about DTC-GT and
desired resources to aid their counseling of these patients.
Data Analysis
STATA statistical software (version 13.1) was utilized for data analysis and statistical
significance was assumed at a Type I error rate of 5% (p < 0.05). Frequencies were reported
for demographic variables. A Friedman’s test with post-hoc analysis was applied to assess for
statistically significant differences in the distribution of the type of genetic testing
recommended between the three sub-scenarios for each individual pedigree (see Results
section). Two comparisons were reported for each pedigree: no prior genetic testing compared
to DTC-GT result, and no prior genetic testing compared to TPI data. For each comparison,
only the participants that recommended genetic testing between both conditions were included.
RESULTS
Of the 1,140 NSGC members eligible to participate, 108 surveys were submitted,
yielding a response rate of 9.5%. Incomplete surveys were excluded, leaving 80 full responses
available for analysis and an overall response rate of 7%. The majority of respondents were
female (75/80, 94%), non-Hispanic Caucasians (72/80, 90%) and employed in university
medical centers (42/80, 53%). There was variability within the region they practiced, the
length of time they have been employed as GCs (IQR 1-5 years), and the proportion of breast
cancer-related indications seen (IQR 50-72%). The demographics of our cohort are consistent
with respondents to the 2019 NSGC Professional Status Survey, with the exception that GCs
practicing in university medical centers were overrepresented in our sample. Of note, none of
our participants indicated that they are employed at DTC-GT companies. Full demographic
information is reported in Table 1.
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Table 1. Demographics of participants (n = 80)
n (%)
Gender (n = 80)
Female
Male
Race (n = 80)
Caucasian
Asian
African American
Other
NSGC Region* (n = 80)
Region 1 (Northeast)
Region 2 (Mid-Atlantic)
Region 3 (Southeast)
Region 4 (Midwest)
Region 5 (Southwest)
Region 6 (Pacific)
Institution Type (n = 80)
University medical center
Private hospital
Public hospital
Physician’s private office
Health maintenance org.
Number of years practicing in
cancer genetics (n = 80)
<1
1 to 3
4-6
7-9
≥ 10
Proportion of breast-related
indications seen (n = 72)
0%
1-25%
26-50%
51-75%
79-100%

75 (94)
5 (6)
72 (90)
3 (4)
1 (2)
4 (4)
5 (6)
11 (14)
8 (10)
26 (32)
20 (25)
10 (13)
42 (53)
18 (22)
15 (19)
2 (4)
1 (2)
15 (19)
32 (40)
19 (24)
6 (7)
8 (10)

2 (3)
4 (6)
17 (24)
37 (51)
12 (16)

*

NSGC Regions:
Region 1: CT, MA, ME, NH, RI, VT, CN, Maritime Provinces
Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec
Experience
Direct-to-Consumer
Genetic Testing Results
Regionwith
3: AL, FL,
GA, KY, LA, MS, NC, SC, TN
Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario
Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask.
Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia, Yukon
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Overall, the majority of participating GCs reported that they have encountered healthrelated DTC-GT results in clinic. Specifically, 94% (75/80) have encountered health-related
23andMe results and 69% (55/80) have encountered health-related TPI data. Within the last
year, participants reported providing counseling for a median of three 23andMe results (IQR 25) and two reports of TPI data (IQR 1-3). Slightly more than half (46/80, 58%) of GCs
indicated that they have had discussions with other GCs and physicians in their clinic
regarding how to address patients’ DTC-GT results in attempts to establish a consensus within
their clinic. In addition, 58% (46/80) indicated that they received information regarding DTCGT counseling in their graduate school training.

Figure 1. Scenario pedigrees (a-c)
a) Scenario 1
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b) Scenario 2

c) Scenario 3
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Scenario-Based Questions for Confirmatory Genetic Testing Recommendations
Participants were given three hypothetical case scenarios designed to ascertain GC
responses when they encountered a patient who brought their DTC-GT result or TPI data to
clinic (Figure 1). Participants were informed that the hypothetical probands in each scenario all
had Ashkenazi Jewish (AJ) ancestry, had no previous clinical-grade genetic testing, did not
have family members available for testing, had completed their cancer treatment, if applicable,
and that the cost of genetic testing was not a factor. Each pedigree was associated with three
sub-scenarios: (A) the proband had no prior genetic testing, (B) the proband underwent DTCGT (23andMe) that reported an AJ pathogenic variant in BRCA1/2, and (C) the proband
underwent DTC-GT and utilized an online TPI service (Promethease) that reported a non-AJ
pathogenic variant in BRCA1/2.
Options for genetic testing recommendations were provided as multiple choice
questions and included: single-site testing of the reported variant (defined as site-specific
testing); the three AJ BRCA1/2 founder mutations or comprehensive testing of BRCA1/2
(which were grouped together and defined as gene-specific testing); a breast cancer panel with
high and moderate penetrance genes, a breast and gynecological cancer panel with genes
related to hereditary breast, ovarian, and gynecological cancer, or a broad cancer panel with
genes related to a multitude of different cancer types (which were grouped together and
defined as multi-gene testing). The data are summarized in Figure 2.
Scenario 1
The first pedigree (Figure 1a) involved a 37-year-old woman diagnosed with breast
cancer at age 33. She has a family history significant for breast cancer diagnosed under age 50
in her mother and maternal cousin and ovarian cancer in her maternal grandmother and
maternal aunt. This pedigree is suggestive of HBOC syndrome. All participants (80/80, 100%)
8

recommended genetic testing for the proband when she presented without prior genetic testing
results, with the majority (72/80, 90%) selecting multi-gene testing. If instead this proband
presented to clinic with a 23andMe result reporting an AJ founder mutation in BRCA1/2, then
77/80 (96%) of participants would recommend confirmatory genetic testing of some degree.
When comparing the 77 participants that recommended genetic testing in both conditions, they
were more likely to select site-specific or gene-specific testing in the presence of the 23andMe
result than when the proband had no previous genetic testing (30/77, 39% v. 7/77, 9%, p <
0.01). A free-response text box was provided to participants who did not recommend clinicalgrade genetic testing; the three participants each indicated a similar response that they trusted
this company to accurately identify the three AJ BRCA1/2 founder mutations. Alternatively, if
this proband presented to clinic with TPI data reporting a non-AJ pathogenic variant in
BRCA1/2, all participants (80/80, 100%) would recommend clinical-grade testing. Most
participants selected a multi-gene testing strategy similar to their recommendations when the
proband had no prior genetic testing (64/77, 83% v. 70/77, 90%, p = 0.62).
Scenario 2
The second pedigree (Figure 1b) involved a 52-year-old woman unaffected with cancer
and a family history that is not suggestive of hereditary cancer. Accordingly, a minority of
participants (25/80, 32%) recommended genetic testing for the proband when she had no prior
genetic testing results. Approximately half of those that did recommend testing (13/25, 52%)
selected the three AJ BRCA1/2 founder mutations. In contrast, if this proband presented to
clinic with a 23andMe result reporting an AJ founder mutation in BRCA1/2, then the majority
of participants (78/80, 97%) would recommend genetic testing. When comparing the 25
participants that recommended testing in both sub-scenarios, about half would still utilize a
targeted testing approach of site-specific or gene-specific testing (14/25, 56% v. 13/25, 52%, p
9

= 0.41). Therefore, the presence of a 23andMe report did not significantly alter the type of
testing recommended amongst these GCs. Similarly, when the proband presented with TPI
data reporting a non-AJ pathogenic variant in BRCA1/2, most GCs (77/80, 96%) would
recommend genetic testing, but half of the GCs included in the comparison (12/25, 48%) still
selected a targeted testing approach. Awareness of the limitations of DTC-GT and TPI services
were cited as the reason amongst participants that did not recommend confirmatory testing.
Scenario 3
The third pedigree (Figure 1c) involved a 60-year-old woman diagnosed with breast
cancer at age 56, with a family history of older onset breast cancers possibly suggestive of
familial, but not hereditary, breast cancer. As this proband meets NCCN guidelines (version
3.2019) for hereditary breast cancer genetic testing, the majority (73/80, 91%) of participating
GCs recommended genetic testing, with most of those (65/73, 89%) recommending multi-gene
testing. If this proband presented with a 23andMe result reporting an AJ founder mutation in
BRCA1/2, then 77/80 (96%) would recommend genetic testing. When comparing the GCs that
recommended testing in both scenarios, they were more likely to select site-specific or genespecific testing in the presence of the 23andMe result than when the proband had no previous
genetic testing (26/73, 36% v. 8/73, 11%, p < 0.01). Alternatively, if this patient presented
with TPI data reporting a non-AJ pathogenic variant in BRCA1/2, then 79/80 (99%) of
participants would recommend genetic testing and were equally as likely to recommend a
multi-gene panel (55/73, 75%, v. 65/73, 89%, p > 0.05) as they were when the proband had no
prior genetic testing.
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Figure 2. Genetic testing recommendations grouped by clinical scenario

Scenario 1: Family history suggestive of HBOC syndrome
n = 77
No prior testing*

23andMe*

TPI
0

10

20
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Number of participants

Scenario 2: Family history not suggestive of hereditary cancer
n = 25

No prior testing

23andMe

TPI
0

2

4
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8

10

12

14

Number of participants
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Scenario 3: Family history suggestive of familial breast cancer
n = 73
No prior testing*

23andMe*

TPI
0

10

20

30

40

50

60

70

Number of participants

*Indicates a significant difference in genetic testing recommendations between conditions (p < 0.05)
Breakdown of genetic testing types recommended by participants, compared between each clinical scenario. Site-specific testing refers to
single-site analysis, gene-specific testing refers to the three Ashkenazi Jewish BRCA1/2 variants and comprehensive BRCA1/2 testing, and
multi-gene testing includes a breast panel, a breast and gynecological cancer panel, and a broad cancer panel with genes related to a multitude
of different cancer types.
TPI = Third-party interpretation

Challenges Associated with Direct-to-Consumer Genetic Testing Reports and Desired
Resources
The majority of participants reported that it is not challenging for them to explain the
need for confirmatory clinical-grade genetic testing (69/80, 86%) or the differences between
clinical and SNP-based genetic testing (49/80, 61%). Approximately half of participants
indicated that it is easy to explain the limited validity of reports from TPI websites (42/80,
53%). Furthermore, 40% (32/80) of participants indicated that managing patient expectations
and anxieties is easy, whereas 30% (24/80) indicated that this task is difficult. There was no
difference in the perceived level of difficulty of all proposed challenges between recent
graduates and more experienced GCs (p > 0.05). Nearly 75% (59/80) of participants agreed
that a patient education document would be a helpful resource to aid their clinical counseling
12

of these patients. They also indicated that practice guidelines (55/80, 69%) or a position
statement (47/80, 59%) from a national genetics society would be helpful resources to guide
their testing recommendations. These results are further summarized in Figure 3.

Figure 3. Likert scale values
Challenges associated with counseling on DTC-GT results in clinic
A.

Explaining confirmatory clinical-grade genetic testing

86%

B. difference between clinical & SNP-based testing
Explaining

61%

Explaining validity of reports from TPI websites

19%

53%

Managing patient expectations and anxieties

Easy

11% 3%

22%

39%

Neutral

32%

20%
25%
30%

Difficult

Desired resources to aid counseling approaches to patients with DTC-GT
Institutional policies
Position statement from a national genetics society

30%

37%

22%

Practice guidelines from a national genetics society

17%

A patient education document

17%

Not At All Helpful

19%

59%

14%

69%

10%
Undecided

33%

73%
Helpful

Reported Likert scale values assessing genetic counselors’ perceived level of difficulty counseling about DTC-GT results in clinic and desired
resources to aid their counseling of these patients.
DTC-GT = Direct-to-consumer genetic testing
SNP = Single nucleotide polymorphism
TPI = Third-party interpretation
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DISCUSSION
Despite the increasing availability of health-related DTC-GT and TPI services, there
has been limited research into the intersection between these types of results and GCs
approaches to clinical genetic testing recommendations. The results of our study indicate that
GCs recommendations are dependent on the personal and family history of the consumer, as
well as if the report is from a DTC-GT company or an online TPI service.
Recommendations for Direct-to-Consumer Genetic Testing Results
The majority of participants would recommend confirmatory clinical-grade genetic
testing for all probands with DTC-GT results, regardless of their personal or family history.
NCCN also recommends confirmatory testing of DTC-GT results because, unlike clinical
genetic tests, DTC-GT is not diagnostic, offer risk information for only a limited set of
conditions, and may be associated with a higher error rate. For these reasons, DTC-GT results
are not intended to impact an individual’s medical management and could lead to
inappropriate changes in patient care (Tandy-Connor et al., 2018).
When presented with a proband affected with breast cancer (scenarios 1 and 3), the
majority of participating GCs recommended multi-gene panel testing. However, if this
proband had a 23andMe result for an AJ BRCA1/2 founder mutation, GCs were overall more
likely to target their testing strategy to recommend site-specific or gene-specific testing. This
finding suggests that these GCs attributed the proband’s cancer history to the variant reported
by the DTC-GT company. However, about half of GCs would still continue to recommend a
multi-gene panel in the presence of this 23andMe result. In an analysis of 1,000 AJ women
with breast cancer, 3% were identified to carry a pathogenic variant in a breast cancer
predisposition gene other than BRCA1/2 (Walsh et al., 2017). This finding demonstrates that
more comprehensive panel testing is an appropriate strategy in these women as it can identify
14

a causative mutation that would otherwise be missed. This may explain why some of our
participants still recommended panel testing in the presence of a reported variant that could
have explained the presenting cancer history.
In contrast, scenario 2 presented a proband that did not have a diagnosis of cancer or a
family history consistent with hereditary cancer. Respondents were equally as likely to
recommend a multi-gene panel when she had no prior genetic testing compared to when she
had a 23andMe result for an AJ BRCA1/2 founder mutation. Our findings suggest that the
presence of a positive DTC-GT BRCA1/2 report influenced this set of GCs testing
recommendations in the presence of a positive personal and/or family history of cancer
(scenarios 1 and 3), but not in the absence of this clinical history (scenario 2).
Recommendations for Third-Party Interpretation Data
Across all clinical scenarios, the presence of TPI data reporting a non-AJ pathogenic
variant in BRCA1/2 did not influence GCs testing recommendations compared to their
recommendations when the proband had no previous genetic testing. Under both conditions,
the majority of GCs recommended multi-gene panels. They also consistently recommended
confirmatory clinical-grade genetic testing for probands with TPI data. While our study was
not designed to identify specific factors that influenced the recommendations made by GCs,
some of the free responses from participants indicated distrust with the analytic validity of
online TPI services to accurately identify pathogenic variants.
These results suggest two key findings related to TPI data and GC recommendations.
First, GCs were more likely to attribute the BRCA1/2 variant reported by the DTC-GT
company as contributing to the cancer history than they were variants reported by TPI
services. Second, participants may believe DTC-GT companies are more accurate in
identifying germline mutations than TPI services. These findings may, in part, be due to the
15

fact that 23andMe has FDA approval to specifically test for the three AJ BRCA1/2 founder
mutations in their CLIA-certified and CAP-accredited laboratory, whereas there are greater
limitations to TPI services, including a 40% false positive rate (Tandy-Connor et al., 2018).
Genetic Counselors’ Clinical Intersection with Direct-to-Consumer Genetic Testing
In 2008, 14% of NSGC members practicing across all specialties reported that they had
provided counseling related to patients’ DTC-GT results (Hock et al., 2011). Our results show
a substantial increase in that figure. Amongst our study population of cancer GCs, 94%
reported providing counseling for 23andMe DTC-GT results, and nearly 70% have provided
counseling for TPI data. The present findings confirm that GCs are increasingly encountering
health-related DTC-GT results as this market continues to expand. This may explain why,
contrary to the findings of Brett et al. (2012) wherein only 7% of surveyed GCs expressed
confidence in accurately interpreting and explaining DTC-GT results, most of our participants
reported that it would be easy for them to navigate potentially challenging aspects of
counseling about DTC-GT results. Examples include explaining the need for confirmatory
clinical-grade genetic testing, the differences between clinical and SNP-based genetic testing,
and the validity of reports from TPI services. These are important counseling skills to have as
data from previous studies indicate that most consumers do not question the validity of their
health-related DTC-GT results and are not seeking further genetic testing (Brett et al., 2012).
Participating GCs were also asked about desired resources to aid their clinical
counseling of these patients. The majority indicated that a position statement and/or practice
guideline from a national genetics society would be helpful. As previously mentioned, NCCN
(2020) advises molecular confirmation of variants identified by commercial companies. In
their position statement, NSGC (2019) recommends that “any genetic variants identified in
raw data files should be confirmed in a clinical laboratory before being used in healthcare
16

decision-making.” Most strongly desired among participants was a patient education document
summarizing the risks and benefits of DTC-GT, how raw data are analyzed, the types of
results that can be obtained, and why confirmatory testing is necessary. Overall, it appears that
GCs would utilize and benefit from the creation of additional patient and professional
resources.
Strengths, Limitations, and Future Directions
This study described the specific genetic testing recommendations that GCs would
make when evaluating a hypothetical patient with positive DTC-GT results or TPI data for
hereditary breast cancer. The ability to interrogate GCs’ recommendations for probands both
affected and unaffected with cancer allowed us to differentiate that clinical history impacts
testing recommendations in the presence of DTC-GT results, but not TPI data. The
demographics of our cohort of GCs are consistent with the larger NSGC membership,
allowing for generalizability of results.
This study had several limitations. Importantly, GCs with stronger opinions about
DTC-GT, or those with greater experience counseling patients for this indication, may have
been more likely to respond to the survey in comparison to GCs with neutral opinions or less
experience counseling on this topic. This may have led to selection bias within our sample.
Therefore, the reported rate that approximately 70-94% of cancer GCs have encountered DTCGT reports in clinic could be an overestimate.
The survey employed for this study was not a formally validated tool, but rather
created by the authors and participants may have interpreted questions differently than
intended. The authors recognize that the GC’s risk assessment and genetic testing decisionmaking process is complex and difficult to capture in a quantitative survey; therefore, certain
testing algorithms were simplified. For example, it is an appropriate genetic testing strategy to
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initiate testing with the three AJ BRCA1/2 founder mutations and subsequently reflex to a
broader panel if necessary. This survey did not take into account how the option of reflex
genetic testing may have influenced participant responses. Lastly, NCCN guidelines were
updated after this study concluded to support testing for hereditary breast cancer genes in all
individuals with AJ ancestry (as were all hypothetical probands in this study), regardless of
their personal cancer status.
While our study captured the genetic testing strategies of GCs specializing in cancer,
DTC-GT results have implications for a wide range of disease types and medical specialties.
23andMe issues carrier status reports for more than 40 autosomal recessive conditions and
health predisposition reports for various multifactorial conditions. Future research should
examine this topic amongst GCs practicing in other specialties to better define how GCs as a
whole implement DTC-GT results into clinical practice. Additionally, it may also be
interesting to examine the relationship between GCs attitudes towards commercial testing and
their recommendations for clinical-grade genetic testing.
Practice Implications
To the best of our knowledge, our study is the first to examine GCs’ genetic testing
recommendations for patients with DTC-GT results or TPI data. GCs’ increasing interaction
with patients seeking guidance on these results, as demonstrated by our findings, highlights the
importance of understanding their approaches to genetic testing. The majority of participating
GCs would recommend confirmatory testing, consistent with guidelines by both NCCN and
NSGC. However, existing guidelines do not advise GCs on which type of confirmatory testing
to order, which is also reflected in our results. Although participants were more likely to
recommend targeted testing in the presence of a positive DTC-GT BRCA1/2 report for a
proband affected with breast cancer, a considerable portion of our sample still recommended a
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multi-gene panel. There was also variability in the breadth of recommended testing to confirm
variants identified by TPI services. While GCs who participated in our study are unified in
their practice of ordering confirmatory testing, the selected clinical-grade test varies depending
on the proband’s cancer history and whether the report was through DTC-GT or TPI services.
Prior studies have shown that GCs may not believe they have the professional
obligation to be knowledgeable about DTC-GT or feel comfortable interpreting these results
(Brett et al., 2012; Hock et al., 2011). Given that the majority of participants in our study
believed that it would be easy to provide counseling related to DTC-GT, it appears that GCs
have made great strides in educating themselves on this topic. As the market for DTC-GT
expands and this patient population continues to grow, GCs must continue to be
knowledgeable on this topic and remain at the forefront of practice-related conversations.
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APPENDIX
Survey Distributed to Genetic Counselors
Qualifying Questions
1. Where do you currently practice as a genetic counselor?
o United States
o Canada
o Other (disqualifying answer)
2. Do you consider clinical cancer genetic counseling as your primary specialty (more
than 50% of your time)?
o Yes
o No (disqualifying answer)
Demographic Questions
1. What is your gender?
o Male
o Female
o Other
o Prefer not to answer
2. What is your age? (text box; require answer to be an integer)
3. What is your race? (Select all that apply)
o American Indian or Alaskan Native
o Asian
o Asian Indian
o Black or African American
o Native Hawaiian or other Pacific Islander
o White or Caucasian
o Prefer not to answer
2. What is your ethnicity?
o Hispanic
o Non-Hispanic
o Prefer not to answer
4. In what region do you practice?
o Region 1: CT, MA, ME, NH, RI, VT, CN, Maritime Provinces
o Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec
o Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN
o Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI,
Ontario
o Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask.
o Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia, Yukon
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5. Please select which best describes your primary place of employment (Select one):
o University medical center
o University/nonmedical center
o Private hospital/medical facility
o Public hospital/medical facility
o Physician’s private practice
o Diagnostic laboratory
o Health maintenance organization
o Telegenetics company
o Other (please specify) (blank text box)
6. Please enter your graduation year from a genetic counseling training program. (text
box; require answer to be an integer)
7. How many years in total have you practiced as a clinical cancer genetic counselor?
(text box; require answer to be an integer)
Genetic Counseling Related Questions
8. Of the patients you have seen in the last year for cancer genetic counseling,
approximately what percentage were breast-related indications (personal and/or family
histories of breast cancer)?
o 0%
o 25%
o 50%
o 75%
o 100%
9. In general, which of the following factors influence your decision on what genetic
testing to recommend for a patient? Please select all that apply:
o Clinical risk assessment
o National Cancer Comprehensive Network (NCCN) guidelines
o Insurance coverage
o Physician preference
o Patient preference
o Institutional policies
10. Does your place of employment have a forum to review genetics cases to elicit
feedback from genetic counselors and/or other medical providers (i.e. case
conference)?
o Yes
o No
11. Which of the following best represents the discussions within your
department/institution regarding how to address direct-to-consumer genetic testing
results in your clinics?
o Our department/institution has not had discussions regarding this topic
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o Our department/institution has had discussions, but a consensus was not
reached on how to address direct-to-consumer genetic testing results in our
clinics
o Our department/institution has developed formal policies (i.e. standard of
practice) regarding how to address direct-to-consumer genetic testing results in
our clinics
o Other: please specify
12. Have you ever counseled a patient who referenced (either by having an electronic or
physical copy and/or mentioning it in the session) their health-related DTC-GT results
in the appointment (for example, 23andMe)? (Not including third party interpretation
reports)
o Yes
o No (skip to question 14)
13. In the last year, how many patients have you counseled regarding their health-related
DTC-GT results (for example, 23andMe)? (text box, require answer be an integer)
14. Have you ever counseled a patient who referenced (either by having an electronic or
physical copy and/or mentioning it in the session) a third-party interpretation of their
health-related DTC-GT results in the appointment (for example, Promethease or
similar websites)?
o Yes
o No (skip to next section)
15. In the last year, how many patients have you counseled regarding a third-party
interpretation of their health-related DTC-GT results (for example, Promethease or
similar websites)? (text box, require answer be an integer)
Scenario #1
Irish Ancestry

Ashkenazi Jewish Ancestry
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You are counseling this proband. She has no previous clinical genetic testing and has already
completed breast cancer treatment before her appointment with you. She reports no one in her
family has ever undergone genetic testing and other family members are unavailable for
testing. The proband does not currently have insurance but is willing to self-pay for any
recommended genetic testing. Consider the following questions and answer according to how
you would approach this in your clinical practice:
1. Would you recommend genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first-tier approach to genetic testing for this
proband?
o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types
o I would recommend a breast and gynecological cancer focused panel including
genes associated with hereditary breast, ovarian, and uterine cancer
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes
o I would recommend the Hereditary Breast and Ovarian Cancer syndrome
related genes (BRCA1 and BRCA2)
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
Consider a different scenario for this same proband. The proband reports that she has had
DTC-GT, specifically through 23andMe, that she obtained by sending in a saliva sample
without direct oversight from a healthcare professional. The DTC-GT company only analyzed
the three Ashkenazi Jewish founder mutations associated with Hereditary Breast and Ovarian
Cancer syndrome (BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT). They also
analyzed other health related-genes outside the context of cancer genetics. The DTC-GT
results identified the following variant in the proband: BRCA1 185delAG. Consider the
following questions:
1. Would you recommend additional genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first-tier approach to genetic testing for this
proband?
23

o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types, which would include the BRCA1 185delAG variant
o I would recommend a breast and gynecological cancer focused panel, which
would include the BRCA1 185delAG variant
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes of which would include the BRCA1
185delAG variant
o I would recommend the Hereditary Breast and Ovarian Cancer syndrome
related genes (BRCA1 and BRCA2), which would include the BRCA1
185delAG variant.
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
o I would recommend single-site testing of the specific BRCA1 185delAG variant
identified by the DTC-GT report
Consider a different scenario for this same proband. The proband reports she has had DTCGT. The DTC-GT company only analyzed the three Ashkenazi Jewish founder mutations
associated with Hereditary Breast and Ovarian Cancer syndrome (BRCA1 185delAG, BRCA1
5382insC, and BRCA2 6174delT). They also analyzed other health related-genes outside the
context of cancer genetics. No relevant variants were detected in cancer related genes. The
proband then elected to download her raw data from the DTC-GT company’s website and
upload it to a third-party interpretation website, specifically Promethease. The proband
presents for genetic counseling with results from the third-party interpretation website that
reported the following: “BRCA1 variant c.3748G>T considered pathogenic for breast cancer.”
Consider the following questions:
1. Would you recommend additional genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first-tier approach to genetic testing for this
proband?
a. I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types, which would include the BRCA1 c.3748G>T variant
b. I would recommend a breast and gynecological cancer focused panel, which
would include the BRCA1 c.3748G>T variant
c. I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes, which would include the BRCA1
c.3748G>T variant
d. I would recommend the Hereditary Breast and Ovarian Cancer syndrome
related genes (BRCA1 and BRCA2), which would include the BRCA1
c.3748G>T variant
e. I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
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f. I would recommend single-site testing of the specific BRCA1 c.3748G>T
variant identified by the third-party interpretation website
Scenario #2
Ashkenazi Jewish Ancestry

Dutch Ancestry

You are counseling this proband. She has no previous clinical genetic testing and reports a
history of normal breast screenings and no history of breast biopsies. She reports no one in her
family has ever undergone genetic testing and other family members are unavailable for
testing. The proband does not currently have insurance but is willing to self-pay for any
recommended genetic testing. Consider the following questions and answer according to how
you would approach this in your clinical practice.
1. Would you recommend genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first-tier approach to genetic testing for this
proband?
o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types
o I would recommend a breast and gynecological cancer focused panel including
genes associated with hereditary breast, ovarian, and uterine cancer
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o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes
o I would recommend the Hereditary Breast and Ovarian Cancer syndrome
related genes (BRCA1 and BRCA2)
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
Consider a different scenario for this same proband. The proband reports that she has had
DTC-GT, specifically through 23andMe, that she obtained by sending in a saliva sample
without direct oversight from a healthcare professional. The DTC-GT company only analyzed
the three Ashkenazi Jewish founder mutations associated with Hereditary Breast and Ovarian
Cancer syndrome (BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT). They also
analyzed other health related-genes outside the context of cancer genetics. The DTC-GT
results identified the following variant in the proband: BRCA2 6174delT. Consider the
following questions:
1. Would you recommend additional genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first tier approach to genetic testing for this
proband?
o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types, which would include the BRCA2 6174delT variant
o I would recommend a breast and gynecological cancer focused panel, which
would include the BRCA2 6174delT variant
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes, which would include the BRCA2
6174delT variant
o I would recommend Hereditary Breast and Ovarian Cancer syndrome related
genes (BRCA1 and BRCA2), which would include the BRCA2 6174delT variant
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
o I would recommend single-site testing of the specific BRCA2 6174delT variant
identified by the DTC-GT report
Consider a different scenario for this same proband. The proband reports she has had DTCGT. The DTC-GT company only analyzed the three Ashkenazi Jewish founder mutations
associated with Hereditary Breast and Ovarian Cancer syndrome (BRCA1 185delAG, BRCA1
5382insC, and BRCA2 6174delT). They also analyzed other health related-genes outside the
context of cancer genetics. No relevant variants were detected in cancer related genes. The
proband then elected to download her raw data from the DTC-GT company’s website and
upload it to a third-party interpretation website, specifically Promethease. The proband
presents for genetic counseling with results from the third-party interpretation website that
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reported the following: “BRCA2 variant aka c.7007G>A considered pathogenic for breast
cancer.” Consider the following questions:
1. Would you recommend additional genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits the first-tier approach to genetic testing for this
proband?
o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types, which would include the BRCA2 c.7007G>A variant
o I would recommend a breast and gynecological cancer focused panel, which
would include the BRCA2 c.7007G>A variant
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes, which would include the BRCA2
c.7007G>A variant
o I would recommend Hereditary Breast and Ovarian Cancer syndrome related
genes (BRCA1 and BRCA2), which would include the BRCA2 c.7007G>A
variant
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
o Single-Site testing of the specific BRCA2 7007G>A variant identified by the
third-party interpretation website.
Scenario #3
English Ancestry

Ashkenazi Jewish Ancestry
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You are counseling this proband. She has no previous clinical genetic testing and has already
completed breast cancer treatment before her appointment with you. She reports no one in her
family has ever undergone genetic testing and other family members are unavailable for
testing. The proband does not currently have insurance but is willing to self-pay for any
recommended genetic testing. Consider the following questions and answer according to how
you would approach this in your clinical practice.
1. Would you recommend genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first-tier approach to genetic testing for this
proband?
o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types
o I would recommend a breast and gynecological cancer focused panel including
genes associated with hereditary breast, ovarian, and uterine cancer
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes
o I would recommend Hereditary Breast and Ovarian Cancer syndrome related
genes (BRCA1 and BRCA2) only
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT) only
Consider a different scenario for this same proband. The proband reports that she has had
DTC-GT, specifically through 23andMe, that she obtained by sending in a saliva sample
without direct oversight from a healthcare professional. The DTC-GT company only analyzed
the three Ashkenazi Jewish founder mutations associated with Hereditary Breast and Ovarian
Cancer syndrome (BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT). They also
analyzed other health related-genes outside the context of cancer genetics. The DTC-GT
results identified the following variant in the proband: BRCA1 5382insC. Consider the
following questions:
1. Would you recommend additional genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits your first tier approach to genetic testing for this
proband?
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o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types, which would include the BRCA1 5382insC variant
o I would recommend a breast and gynecological cancer focused panel, which
would include the BRCA1 5382insC variant
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes, which would include the BRCA1
5382insC variant
o I would recommend Hereditary Breast and Ovarian Cancer syndrome related
genes (BRCA1 and BRCA2), which would include the BRCA1 5382insC variant
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
o I would recommend single-site testing of the specific BRCA1 5382insC variant
identified by the DTC-GT report
Consider a different scenario for this same proband. The proband reports she has had DTCGT. The DTC-GT company only analyzed the three Ashkenazi Jewish founder mutations
associated with Hereditary Breast and Ovarian Cancer syndrome (BRCA1 185delAG, BRCA1
5382insC, and BRCA2 6174delT). They also analyzed other health related-genes outside the
context of cancer genetics. No relevant variants were detected in cancer related genes. The
proband then elected to download her raw data from the DTC-GT company’s website and
upload it to a third-party interpretation website, specifically Promethease. The proband
presents for genetic counseling with results from the third-party interpretation website that
reported the following: “BRCA1 variant aka c.5095C>T considered pathogenic for breast
cancer.” Consider the following questions:
1. Would you recommend additional genetic testing for this proband?
o Yes
o No
Yes = Give following question.
No = Free response question = Please explain your reasoning for not considering genetic
testing for this proband.
2. Which of the following best fits the first-tier approach to genetic testing for this
proband?
o I would recommend a broad cancer panel associated with a wide range of
cancer/tumor types, which would include the BRCA1 c.5095C>T variant
o I would recommend a breast and gynecological cancer focused panel, which
would include the BRCA1 c.5095C>T variant
o I would recommend a breast cancer focused panel including high and moderate
penetrant breast cancer related genes, which would include the BRCA1
c.5095C>T variant
o I would recommend the Hereditary Breast and Ovarian Cancer syndrome
related genes (BRCA1 and BRCA2), which would include the BRCA1
c.5095C>T variant
o I would recommend the three Ashkenazi Jewish founder mutations (BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT)
29

o I would recommend single-site testing of the specific BRCA1 c.5095C>T
variant identified by the third-party interpretation website
Educational/Resource Questions
1. In your genetic counseling graduate school training, did you receive information
regarding DTC-GT?
o Yes
o No
2. Please indicate how you received information regarding DTC-GT in your training
program: (select all that apply)
o Class lectures
o Clinical rotations
o Journal club
o Case conferences
o Research articles
o Other (Please specify): (text box)
3. Have you attended any online seminars or talks at educational conferences regarding
DTC-GT?
o Yes
o No

4.
5. What is the most notable challenge(s) that you face when counseling about DTC-GT in
clinic? (text box, free response)
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6.
7. In addition to the resources listed above, are there any other resources that would be
helpful regarding counseling about DTC-GT results? (text box, free response)
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